Clinical Trials

View All Clinical Trials

The results of your search are listed below. To view the details of a trial or study, click on the "see details >" link. Or start a new search.

No search term entered. 289 results shown below.

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

[Complete title: HLA-haploidentical Related Marrow Grafts for the Treatment of Primary Immunodeficiencies and Other Nonmalignant Disorders Using Conditioning with Low-dose Cyclophosphamide, TBI and Fludarabine and Postgrafting Cyclophosphamide]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2032.00
Phase: II

Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders

[Complete title: Low-dose TBI Dose Escalation to Decrease Risks of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning as Treatment for Untreated Myelodysplastic Syndrome or Myeloproliferative Disorders -- A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2056.00
Phase: II

Nonmyeloablative transplant for severe systemic sclerosis

[Complete title: Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning for Patients with Severe Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2067.00
Phase: I/II

Gene Therapy for Fanconi Anemia

[Complete title: Gene Transfer for Patients with Fanconi Anemia Complementation Group A (FANCA)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 2097.00
Phase: I

Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

[Complete title: Allogeneic Hematopoietic Cell Transplantation for Patients with Nonmalignant Inherited Disorders Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Lauri Burroughs, MD
Study Number: 2256.00
Phase: II

Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

[Complete title: Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2368.00
Phase: NA

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

[Complete title: A phase II trial of high-dose 90Y-Ibritumomab tiuxetan (anti-CD20) followed by fludarabine and low-dose total body irradiation and HLA-matched allogeneic hematopoietic transplantation for patients with relapsed or refractory aggressive B-cell lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 2398.00
Phase: II

Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study of Optimally Dosed Clofarabine in Combination with Low-Dose TBI to Decrease Relapse Rates after Related or Unrelated Donor Hematopoietic Cell Transplantation in Patients with AML]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2430.00
Phase: II

90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

[Complete title: A Phase I Study of 90Y-BC8-DOTA monoclonal antibody, Fludarabine and TBI Followed by HLA-Matched, Allogeneic Peripheral Blood Stem Cell Transplant for the Treatment of Multiple Myeloma]
Principal Investigator: Damian Green, MD
Study Number: 2450.00
Phase: I

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

[Complete title: A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009)]
Principal Investigator: Edward Libby
Study Number: 2477.00
Phase: III

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

[Complete title: AMC PROTOCOL #075: A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin’s Lymphoma. A Trial of the AIDS Malignancy Consortium (AMC)]
Principal Investigator: Manoj Menon
Study Number: 2483.00
Phase: I/II

Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

[Complete title: Phase I/II Study of Adoptive Immunotherapy with Virus Specific CD8+ T Cells that have been Transduced to Express a WT1-Specific T Cell Receptor for Patients with High Risk or Relapsed AML, MDS, or CML]
Principal Investigator: Daniel Egan
Study Number: 2498.00
Phase: I/II

Scleroderma Treatment with Autologous Transplant (STAT) Study

[Complete title: A Phase II Multi-Center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation for the Treatment of Systemic Sclerosis]
Principal Investigator: George Georges, MD
Study Number: 2533.00
Phase: II

Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

[Complete title: Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients with AML or Acute Leukemia of Ambiguous Lineage]
Principal Investigator: Ann Dahlberg
Study Number: 2584.00
Phase: Pilot

Donor Umbilical Cord Blood Transplant With or Without Ex-Vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes

[Complete title: Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies]
Principal Investigator: Filippo Milano
Study Number: 2603.00
Phase: II

Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

[Complete title: A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma S/P Autologous Hematopoietic Cell Transplantation]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 2620.00
Phase: II

Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality

[Complete title: Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality]
Principal Investigator: Roland Walter, MD
Study Number: 2642.00
Phase: Pilot

Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma

[Complete title: Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion with Cyclophosphamide and Fludarabine For Patients With Metastatic Melanoma]
Principal Investigator: Sylvia Lee, MD
Study Number: 2643.00
Phase: II

Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study]
Principal Investigator: Anna Halpern
Study Number: 2652.00
Phase: I/II

Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children

[Complete title: A Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children]
Principal Investigator: Marie Bleakley, MD
Study Number: 2660.00
Phase: II

Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant (ICT-HCT)

[Complete title: Initial Cytoreductive Therapy for Myelodysplastic Syndrome prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)]
Principal Investigator: Bart Scott, MD
Study Number: 2661.00
Phase: II

Abatacept as GVHD Prophylaxis Phase 2

[Complete title: Abatacept Combined with a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial]
Principal Investigator: Leslie Kean
Study Number: 2692.00
Phase: II

Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma

[Complete title: A Pilot Study to Test whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients with Synovial Sarcoma and Myxoid / Round Cell Liposarcoma]
Principal Investigator: Seth Pollack
Study Number: 2705.00
Phase: Pilot

Chronic GVHD Response Measures Validation

[Complete title: Chronic GVHD Response Measures Validation]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 2710.00
Phase: NA

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

[Complete title: AMC Protocol #085: A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma]
Principal Investigator: Manoj Menon
Study Number: 2719.00
Phase: I/II

NY-ESO-1-specific T Cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy

[Complete title: A pilot trial of NY-ESO-1-specific T cells in patients with metastatic NY-ESO-1-expressing sarcomas receiving palliative radiation]
Principal Investigator: Seth Pollack
Study Number: 2721.00
Phase: I

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

[Complete title: A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)]
Principal Investigator: Roland Walter, MD
Study Number: 2734.00
Phase: I/II

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

[Complete title: Molecular Correlates of Sensitivity and Resistance to Therapy in Genitourinary Malignancy]
Principal Investigator: Robert Montgomery, MD
Study Number: 6932
Phase: NA

F-18 FES PET in Measuring Hormone Expression in Patients with Primary, Recurrent or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy

[Complete title: Serial [F-18] fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy]
Principal Investigator: Hannah Linden, MD
Study Number: 7184
Phase: NA

FLAX FX, A research study of the effects of flaxseed lignans on colon health
Principal Investigator: Johanna Lampe, PhD, RD
Study Number: 7532
Phase: NA

Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel

[Complete title: A Phase II Study of MAOA Inhibitor Plus Docetaxel in Patients Receiving and Progressing on Docetaxel Therapy]
Principal Investigator: Evan Yu, MD
Study Number: 7563
Phase: II

Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms

[Complete title: Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study]
Principal Investigator: Heidi Gray, MD
Study Number: 7750
Phase: Pilot

18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors

[Complete title: Cellular Proliferation Imaging Using [18F]fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors]
Principal Investigator: Jason Rockhill
Study Number: 7754
Phase: NA

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

[Complete title: A Phase II Study of Weekly ABRAXANE® for Patients with Advanced NSCLC with EGFR Mutations or with Durable Response to an EGFR Tyrosine Kinase Inhibitor following Front-Line Therapy with EGFR Tyrosine Kinase Inhibitors]
Principal Investigator: Christina Baik
Study Number: 7755
Phase: II

Cabozantinib in Treating Men With Hormone-Resistant Prostate Cancer

[Complete title: A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 7819
Phase: Pilot

Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer

[Complete title: Degarelix Acetate Prior to Radiation Therapy]
Principal Investigator: Robert Montgomery, MD
Study Number: 7846
Phase: Pilot

Ado-Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery

[Complete title: Thrombokinetic Studies of Trastuzumab Emtansine]
Principal Investigator: V.K. Gadi, MD, PhD
Study Number: 7900
Phase: I

Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

[Complete title: Feasibility of Outpatient Induction Chemotherapy for Adult Patients with Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 7910
Phase: Pilot

Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery

[Complete title: NU 11I03: A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)]
Principal Investigator: Gabriela Chiorean
Study Number: 8007
Phase: I/II

Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer

[Complete title: PET Imaging as a Biomarker of Systemic Treatment Response for Men with Metastatic Castration-Resistant Prostate Cancer]
Principal Investigator: Evan Yu, MD
Study Number: 8021
Phase: NA

Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer

[Complete title: A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients with Bladder Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 8027
Phase: I/II

CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) after Completion of Standard FDA Approved therapy with Sipuleucel-T (Provenge®) for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castration-resistant Prostate Cancer (mCRPC)]
Principal Investigator: Evan Yu, MD
Study Number: 8037A
Phase: II

A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer

[Complete title: A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer]
Principal Investigator: Robert Montgomery, MD
Study Number: 8040
Phase: II

Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer

[Complete title: Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)]
Principal Investigator: Hannah Linden, MD
Study Number: 8093
Phase: II

MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer

[Complete title: MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix]
Principal Investigator: Nina Mayr, MD
Study Number: 8118
Phase: NA

Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin (ITOMIC)

[Complete title: Intensive Trial of OMics in Cancer (ITOMIC) 001- Intensive Longitudinal Monitoring in Patients with Triple Negative Breast Cancer]
Principal Investigator: Tony Blau, MD
Study Number: 8132
Phase: Pilot

SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy

[Complete title: Pulmonary Functional Imaging for Radiation Treatment Planning]
Principal Investigator: Jing Zeng
Study Number: 8180
Phase: Pilot

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

[Complete title: Decitabine plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 9019
Phase: II

A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma

[Complete title: A Phase 2, Multi-Center Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma]
Principal Investigator: Andrei Shustov, MD
Study Number: 9023
Phase: II

Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

[Complete title: RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy followed by Ipilimumab in Metastatic Melanoma]
Principal Investigator: Ramesh Rengan
Study Number: 9031
Phase: II

JAK-2 Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

[Complete title: JAK-2 Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients with Primary and Secondary Myelofibrosis: A Prospective Study]
Principal Investigator: Rachel Salit
Study Number: 9033
Phase: II

Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer With Correlative Assessment of Androgen Receptor Signaling

[Complete title: Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) with Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing]
Principal Investigator: Robert Montgomery, MD
Study Number: 9055
Phase: II

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

[Complete title: A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients with Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)]
Principal Investigator: Ajay Gopal, MD
Study Number: 9111
Phase: I/II

Allo vs. Hypomethylating/Best Supportive Care in MDS

[Complete title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome]
Principal Investigator: Bart Scott, MD
Study Number: 9129
Phase: III

Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

[Complete title: A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients]
Principal Investigator: Nora Disis, MD
Study Number: 9140
Phase: I

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

[Complete title: A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) with Radiation in Patients with Metastatic Sarcoma]
Principal Investigator: Seth Pollack
Study Number: 9145
Phase: I

Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy

[Complete title: Definitive Re-Irradiation with Proton Beam Radiotherapy for Patients with Recurrent Thoracic Cancers]
Principal Investigator: Jing Zeng
Study Number: 9148
Phase: Pilot

Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors

[Complete title: Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)]
Principal Investigator: K.Scott Baker
Study Number: 9161
Phase: II

AZD1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck

[Complete title: A Phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin prior to surgery in squamous cell carcinoma of the head and neck (HNSCC)]
Principal Investigator: Eddie Mendez
Study Number: 9168
Phase: I

Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer

[Complete title: Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer]
Principal Investigator: Eddie Mendez
Study Number: 9188
Phase: II

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

[Complete title: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 9198
Phase: II

Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation

[Complete title: Prevention of Bone Loss after Pediatric Hematopoietic Cell Transplantation]
Principal Investigator: K.Scott Baker
Study Number: 9223
Phase: II

Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease

[Complete title: Carfilzomib for Treatment of Chronic Graft-versus-Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9228
Phase: II

Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma

[Complete title: Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination with MHC Class I Up-regulation and the Anti-PD-L1 Antibody Avelumab]
Principal Investigator: Aude Chapuis, MD
Study Number: 9245
Phase: I/II

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

[Complete title: Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy after Autologous Transplant for Treating Multiple Myeloma.]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 9266
Phase: II

Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy

[Complete title: Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy]
Principal Investigator: Jonathan Wright
Study Number: 9274
Phase: II/III

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma

[Complete title: MK-3475 in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 9291
Phase: II

Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease

[Complete title: Ixazomib for Treatment of Chronic Graft-versus-Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9292
Phase: II

Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers

[Complete title: A Pilot Feasibility Study: Taking Care of Her]
Principal Investigator: Frances Lewis
Study Number: 9306
Phase: Pilot

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer (PARTIQoL)

[Complete title: PARTIQol: Prostate Advance Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer]
Principal Investigator: Jing Zeng
Study Number: 9328
Phase: III

Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

[Complete title: Androgen Receptor Targeting in Mantle Cell Lymphoma : A Pilot Trial of Enzalutamide]
Principal Investigator: Ajay Gopal, MD
Study Number: 9340
Phase: Pilot

Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance (Transformer)

[Complete title: A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamidein Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)]
Principal Investigator: Michael Schweizer
Study Number: 9342
Phase: II

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

[Complete title: The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)]
Principal Investigator: Vivian Oehler, MD
Study Number: 9361
Phase: II

Docetaxel and Carboplatin in Treating Patients With Metastatic, Hormone Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

[Complete title: A Pilot Study of Docetaxel and Carboplatin for treatment of patients with metastatic, castration resistant prostate cancer containing biallelic inactivation of genes in the BRCA1/2 pathway]
Principal Investigator: Heather Cheng
Study Number: 9381
Phase: Pilot

Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

[Complete title: A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients with Metastatic, Castration Resistant Prostate Cancer: (Rapamycin inhibition of DDSP (RID))]
Principal Investigator: Robert Montgomery, MD
Study Number: 9388
Phase: I/II

Niclosamide and Enzalutamide in Treating Patients With Androgen Receptor Splice Variant-Positive, Castration-Resistant, Metastatic Prostate Cancer

[Complete title: A Phase I Study of Niclosamide in Combination with Enzalutamide in Men with Androgen Receptor Splice Variant Positive Castration-Resistant Prostate Cancer]
Principal Investigator: Michael Schweizer
Study Number: 9390
Phase: I

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

[Complete title: A randomized Phase II study of adjuvant Trastuzumab emtansine (T-DM1) vs. Paclitaxel in combination with Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT Trial)]
Principal Investigator: V.K. Gadi, MD, PhD
Study Number: 9409
Phase: II

Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors

[Complete title: Developing an Intervention to Reduce Stress and Improve Quality of Life in Underserved Urban Latina Breast Cancer Survivors]
Principal Investigator: Rachel Ceballos
Study Number: 9425
Phase: NA

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

[Complete title: Continued, Long-Term Follow-up and Lenalidomide Maintenance Therapy for Patients Who Have Enrolled on BMT CTN 0702]
Principal Investigator: Leona Holmberg, MD, PhD
Study Number: 9485
Phase: III

Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

[Complete title: Ofatumumab in Combination with Glucocorticoids for Primary Therapy of Chronic Graft vs. Host Disease]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9514
Phase: II

Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy

[Complete title: A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy]
Principal Investigator: Janice Kim, MD
Study Number: A011202
Phase: III

Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

[Complete title: ACNS0332, Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0332
Phase: III

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

[Complete title: A Randomized Phase II Trial of Myeloablative versus Non-myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma]
Principal Investigator: Maciej Mrugala, MD, PhD
Study Number: C51101
Phase: II

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

[Complete title: Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01: (see comment for full title)]
Principal Investigator: Julie Park, MD
Study Number: ENCIT-01
Phase: I

Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery

[Complete title: A Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA , Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphadenectomy]
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0263
Phase: III

Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy

[Complete title: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy]
Principal Investigator: Heidi Gray, MD
Study Number: GOG 0724/ RTOG 0724
Phase: III

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia (Interfant06)

[Complete title: Interfant 06: International Collaborative Treatment Protocol For Infants Under One Year with Acute Lymphoblastic Leukemia or Biphenotypic Leukemia]
Principal Investigator: Rebecca Gardner, MD
Study Number: Interfant-06

A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

[Complete title: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia]
Principal Investigator: Rebecca Gardner, MD
Study Number: PLAT-02
Phase: I/II

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

[Complete title: SWOG: A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL)]
Principal Investigator: Oliver Press, MD, PhD
Study Number: S1001
Phase: II

Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

[Complete title: SC-4002, An Open Label, Expanded Access Protocol Using 131I - Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma]
Principal Investigator: Julie Park, MD
Study Number: SC-4002

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide in Patients With Previously Treated, Incurable Ewing Sarcoma

[Complete title: ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib, and Temozolomide in Patients with Previously Treated, Incurable Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-6015
Phase: I

A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis

[Complete title: A Pilot Study Evaluating the use of the mTOR Inhibitor Sirolimus in Children and Young Adults with Desmoid-Type Fibromatosis]
Principal Investigator: Doug Hawkins, MD
Study Number: SC-6016
Phase: Pilot

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

[Complete title: SC-9002: A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paciltaxel, and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) and Autologous Hematopoeitic Stem Cell Rescue (AuHSCR) for patients with…]
Principal Investigator: Sarah Leary
Study Number: SC-9002
Phase: II

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)

[Complete title: Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas]
Principal Investigator: Sarah Leary
Study Number: SC-9005
Phase: II

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors (SEED)

[Complete title: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients with Refractory or Recurrent Brain Tumors]
Principal Investigator: Sarah Leary
Study Number: SC-9006
Phase: Pilot

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

[Complete title: Transplantation of Umbilical Cord Blood for Patients with Hematological Diseases with Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen]
Principal Investigator: Colleen Delaney, MD, MSc
Study Number: 2010.00
Phase: II

A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

[Complete title: A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas]
Principal Investigator: Elizabeth Loggers
Study Number: 20132286
Phase: II

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

[Complete title: Hematopoietic Bone Marrow Transplantation for Patients with High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) using Related HLA-Mismatched Donors: A Trial Using Radiolabeled Anti-CD45 Antibody Combined with Immunosuppression Before and After Transplantation]
Principal Investigator: Johnnie Orozco, MD, PhD
Study Number: 2186.00
Phase: II

Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients With Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Phase II Study to Assess Immunosuppression with Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD after Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation – A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2206.00
Phase: II

Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer

[Complete title: Human Immunodeficiency Virus (HIV)-Specific Immune Reconstitution after Myeloablative Hematopoietic Cell Transplant for Treatment of Hematologic Malignancy in Patients Infected with HIV]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2212.00
Phase: II

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

[Complete title: A Phase I/II Study Evaluating the Safety and Efficacy of Adding a Single Prophylactic Donor Lymphocyte Infusion (DLI) of Natural Killer Cells Early After Nonmyeloablative, HLA-Haploidentical Hematopoietic Cell Transplantation]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2230.00
Phase: I/II

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

[Complete title: A Study Evaluating Escalating Doses of 131I-BC8 (anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2238.00
Phase: I

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Reduced-intensity Preparative Regimen]
Principal Investigator: Rachel Salit
Study Number: 2239.00
Phase: II

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

[Complete title: Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT using Related, HLA-Haploidentical Donors for Patients with High-Risk lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2241.00
Phase: II

Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

[Complete title: High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients with Autoimmune Neurologic Diseases]
Principal Investigator: George Georges, MD
Study Number: 2260.00
Phase: II

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Donor Umbilical Cord Blood Transplant

[Complete title: Transplantation of Umbilical Cord Blood in Patients with Hematological Malignancies Using a Treosulfan Based Preparative Regimen]
Principal Investigator: Filippo Milano
Study Number: 2275.00
Phase: II

Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

[Complete title: Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients with Hematologic Malignancies using Related, HLA-Haploidentical Donors: A Phase II trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source]
Principal Investigator: Rachel Salit
Study Number: 2372.00
Phase: II

Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant

[Complete title: A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor Hematopoietic Cell Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2448.00
Phase: III

Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

[Complete title: A Study Evaluating Escalating Doses of 90Y-DOTA-BC8 (anti-CD45) Antibody followed by Allogeneic Stem Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML) Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2468.00
Phase: I

Treosulfan and Fludarabine Phosphate With or Without Total Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

[Complete title: A Randomized Phase II Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)]
Principal Investigator: Joachim Deeg, MD
Study Number: 2524.00
Phase: II

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

[Complete title: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2531.00
Phase: NA

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

[Complete title: Donor Statin Treatment for Prevention of Severe Acute GVHD after Nonmyeloablative Hematopoietic Cell Transplantation]
Principal Investigator: Marco Mielcarek, MD
Study Number: 2546.00
Phase: II

Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant

[Complete title: A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, To Treat Patients with Persistent or relapsed B-cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation.]
Principal Investigator: Mohamed Sorror, MD, MSc
Study Number: 2561.00
Phase: II

Alpha 1 Anti-Trypsin in Treating Patients With Acute Graft-Versus-Host Disease

[Complete title: Treatment of Steroid Non-responsive Acute GVHD with Alpha 1 Anti-trypsin (AAT). A Phase I/II Study]
Principal Investigator: Joachim Deeg, MD
Study Number: 2571.00
Phase: I/II

Double Cord Versus Haploidentical (Blood and Marrow Transplant Clinical Trials Network #1101)

[Complete title: A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow for Patients with Hematologic Malignancies]
Principal Investigator: Rachel Salit
Study Number: 2580.00
Phase: III

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

[Complete title: Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma with Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor]
Principal Investigator: David Maloney, MD, PhD
Study Number: 2639.00
Phase: I/II

Selective Depletion of CD45RA+ Naive T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD

[Complete title: A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors for Prevention of GVHD]
Principal Investigator: Marie Bleakley, MD
Study Number: 2684.00
Phase: II

Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma

[Complete title: Phase I/II study in WT1-expressing non-small cell lung cancer and mesothelioma, comparing cellular adoptive immunotherapy with polyclonal autologous central memory to naïve CD8+ T cells that have been transduced to express a WT1-specific T cell receptor]
Principal Investigator: Sylvia Lee, MD
Study Number: 2727.00
Phase: I/II

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

[Complete title: A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (anti-CD45) Antibody followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies]
Principal Investigator: Ajay Gopal, MD
Study Number: 2728.00
Phase: I/II

Cognitive Rehabilitation in Cancer Survivors: A Pilot Study
Principal Investigator: Monique Cherrier, PhD
Study Number: 7279
Phase: NA

Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer

[Complete title: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally - Advanced Resected Head and Neck Cancer]
Principal Investigator: George Laramore, MD, PhD
Study Number: 7428
Phase: III

Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma

[Complete title: Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma]
Principal Investigator: George Laramore, MD, PhD
Study Number: 8078
Phase: III

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

[Complete title: Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination with Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers]
Principal Investigator: Gabriela Chiorean
Study Number: 9078
Phase: I

Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy

[Complete title: Integrating a Telemonitoring Device into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study]
Principal Investigator: Anna Halpern
Study Number: 9105
Phase: Pilot

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma

[Complete title: A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 9107
Phase: Pilot

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy (RAFA)

[Complete title: A Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction with Busulfan, Cyclophosphamide and Fludarabine]
Principal Investigator: K.Scott Baker
Study Number: 9213
Phase: II

COcoa Supplement and Multivitamin Outcomes Study (COSMOS)

[Complete title: The Cocoa Supplement and Multivitamin Outcomes Study (COSMOS) Trial Protocol]
Principal Investigator: Garnet Anderson, PhD
Study Number: 9214
Phase: NA

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

[Complete title: Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 9226
Phase: Pilot

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

[Complete title: A single arm Phase I/II study of MK-3475 combined with vorinostat for recurrent unresectable and/or metastatic squamous cell head and neck cancer and recurrent unresectable and/or metastatic salivary gland malignancies]
Principal Investigator: Tina Rodriguez, MD
Study Number: 9383
Phase: I/II

Hypnotherapy in Treating Chronic Pain in Cancer Survivors

[Complete title: Hypnosis for Pain Relief with Cancer Survivors]
Principal Investigator: Kathleen Shannon Dorcy, PhD, RN, MN
Study Number: 9445
Phase: Pilot

Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Children

[Complete title: The Enhancing Connections Program in Palliative Care: Taking Care of the Children]
Principal Investigator: Frances Lewis
Study Number: 9480
Phase: Pilot

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

[Complete title: A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer (GOG-0281)]
Principal Investigator: Heidi Gray, MD
Study Number: GOG-0281
Phase: II/III

Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-Small Cell Lung Cancer, or Head and Neck Cancer

[Complete title: A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Head and Neck Cancer]
Principal Investigator: John Thompson, MD
Study Number: 7637a
Phase: I

Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma

[Complete title: RTOG 1205: Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma]
Principal Investigator: George Laramore, MD, PhD
Study Number: 8024
Phase: II

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer

[Complete title: A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)]
Principal Investigator: Paul Nghiem
Study Number: 8269a
Phase: II

A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Melanoma

[Complete title: A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients with Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer]
Principal Investigator: Sylvia Lee, MD
Study Number: 9103A
Phase: I

S1313, Combination Chemotherapy With or Without PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

[Complete title: S1313, A Phase Ib/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma]
Principal Investigator: Gabriela Chiorean
Study Number: 9118
Phase: I/II

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer (e3)

[Complete title: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: 9174
Phase: III

Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management

[Complete title: A Phase II Multicenter Randomized Trial Evaluating 3-year Disease-Free Survival in Patients with Locally Advanced Rectal Cancer treated with Chemoradiation plus Induction or Consolidation Chemotherapy, and Total Mesorectal Excision or Non-Operative Management]
Principal Investigator: Andrew Coveler, MD
Study Number: 9240
Phase: II

S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer

[Complete title: A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer]
Principal Investigator: Heather Cheng
Study Number: 9293
Phase: III

Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery

[Complete title: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision]
Principal Investigator: Gabriela Chiorean
Study Number: 9412
Phase: II/III

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

[Complete title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)]
Principal Investigator: Rafael Santana-Davila
Study Number: A081105
Phase: III

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

[Complete title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)]
Principal Investigator: Rafael Santana-Davila
Study Number: A151216
Phase: NA

Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

[Complete title: AALL0932, Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL).]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL0932
Phase: III

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

[Complete title: AALL1131: A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum]
Principal Investigator: Doug Hawkins, MD
Study Number: AALL1131
Phase: III

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

[Complete title: AALL1231, A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T- Lymphoblastic Leukemia (T-ALL) and T- Lymphoblastic Lymphoma (T-LLy)]
Principal Investigator: Kasey Leger, MD
Study Number: AALL1231
Phase: III

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

[Complete title: AALL1331, Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)]
Principal Investigator: Rebecca Gardner, MD
Study Number: AALL1331
Phase: III

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

[Complete title: AALL1131, A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD.]
Principal Investigator: Doug Hawkins, MD
Study Number: AAML1031
Phase: III

Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

[Complete title: AAML1331, A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid]
Principal Investigator: Todd Cooper
Study Number: AAML1331
Phase: III

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

[Complete title: ACNS0821, Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus evacizumab (NSC# 704865, BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0821
Phase: II

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

[Complete title: ACNS0831, Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS0831
Phase: III

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

[Complete title: ACNS1022, A Phase II Randomized Trial of Lenalidomide (NSC # 703813, IND # 70116) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS1022

Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

[Complete title: ACNS1123, Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS1123
Phase: II

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma

[Complete title: ACNS1221, A Phase II Study For The Treatment Of Non-Metastatic Nodular Desmoplastic Medulloblastoma In Children Less Than 4 Years Of Age]
Principal Investigator: Doug Hawkins, MD
Study Number: ACNS1221
Phase: II

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

[Complete title: ADVL1212, A Phase I Study of Crizotinib in Combination with Conventional Chemotherapy for Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (ALCL)]
Principal Investigator: Julie Park, MD
Study Number: ADVL1212
Phase: I

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas. (BOLD 113)

[Complete title: ADVL1314, A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (excluding CNS), including Lymphomas]
Principal Investigator: Doug Hawkins, MD
Study Number: ADVL1314
Phase: I

VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors

[Complete title: ADVL1315, A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# 123101) in Children with Recurrent or Refractory Solid Tumors.]
Principal Investigator: Julie Park, MD
Study Number: ADVL1315
Phase: I/II

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

[Complete title: A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab]
Principal Investigator: Julie Park, MD
Study Number: ADVL1412
Phase: I/II

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

[Complete title: AEWS1031, A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS1031
Phase: III

Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

[Complete title: AEWS1221, Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma]
Principal Investigator: Doug Hawkins, MD
Study Number: AEWS1221
Phase: II

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

[Complete title: AHEP0731, Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782, NSC#683864) Added to High Risk Stratum Treatment]
Principal Investigator: Doug Hawkins, MD
Study Number: AHEP0731
Phase: III

Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Hodgkin Lymphoma

[Complete title: AHOD1331, A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents]
Principal Investigator: Doug Hawkins, MD
Study Number: AHOD1331
Phase: III

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

[Complete title: ANBL1232, Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma. A Groupwide Historically Controlled Phase III Study]
Principal Investigator: Julie Park, MD
Study Number: ANBL1232
Phase: III

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

[Complete title: ANHL12P1, A Randomized Phase II Trial of Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)]
Principal Investigator: Rebecca Gardner, MD
Study Number: ANHL12P1

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

[Complete title: Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)]
Principal Investigator: Doug Hawkins, MD
Study Number: ARST1321
Phase: II

A Single Arm Trial of Systemic and Subtenon Chemotherapy for Group C/D Intraocular Retinoblastoma
Principal Investigator: Doug Hawkins, MD
Study Number: COG ARET0231
Phase: III

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

[Complete title: Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB ? R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV? R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB ? LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ? LR)]
Principal Investigator: Brian Till, MD
Study Number: E1411
Phase: II

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

[Complete title: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)]
Principal Investigator: Mazyar Shadman
Study Number: E1912
Phase: III

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

[Complete title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein]
Principal Investigator: Rafael Santana-Davila
Study Number: E4512
Phase: III

131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat (N2011-01)

[Complete title: NANT 2011-01: STUDY OF SINGLE-AGENT 131I-MIBG, 131I-MIBG WITH VINCRISTINE AND IRINOTECAN, OR 131I-MIBG WITH VORINOSTAT FOR RESITANT/RELAPSED NEUROBLASTOMA]
Principal Investigator: Julie Park, MD
Study Number: NANT 2011-01
Phase: II

Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma

[Complete title: NANT 2011-04: A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients with Refractory/Recurrent Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: NANT 2011-04
Phase: II

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

[Complete title: NANT 2012-01 PHASE I STUDY OF DIFLUOROMETHYLORNITHINE (DFMO) AND CELECOXIB WITH CYCLOPHOSPHAMIDE/TOPOTECAN FOR PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA]
Principal Investigator: Julie Park, MD
Study Number: NANT 2012-01
Phase: I

SF1126 for Patients With Relapsed or Refractory Neuroblastoma

[Complete title: NANT 2014-01 Phase I Study of SF1126 for Patients with Relapsed or Refractory Neuroblastoma]
Principal Investigator: Julie Park, MD
Study Number: NANT 2014-01
Phase: I

Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

[Complete title: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma]
Principal Investigator: Lia Halasz
Study Number: NRG-BN001
Phase: II

Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer

[Complete title: RANDOMIZED PHASE II TRIAL OF POSTOPERATIVE ADJUVANT IMRT FOLLOWING CYSTECTOMY FOR pT3/pT4 UROTHELIAL BLADDER CANCER]
Principal Investigator: Jing Zeng
Study Number: NRG-GU001
Phase: II

Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery

[Complete title: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy]
Principal Investigator: Janice Kim, MD
Study Number: NSABP B-51 / RTOG 1304
Phase: III

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

[Complete title: Phase I Study of CDK 4-6 Inhibitor PD-0332991 In Children With Recurrent, Progressive or Refractory Central Nervous System Tumors]
Principal Investigator: Sarah Leary
Study Number: PBTC-042
Phase: I

PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children

[Complete title: Phase II Study of everolimus for recurrent or progressive low-grade gliomas in children]
Principal Investigator: Sarah Leary
Study Number: PNOC001
Phase: II

Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

[Complete title: Safety, Phase 0, and Pilot Efficacy Study of vemurafenib, an oral inhibitor of BRAFV600E, in Children and Young Adults with Recurrent/Refractory BRAFV600E-or BRAF Ins T mutant gliomas]
Principal Investigator: Sarah Leary
Study Number: PNOC002
Phase: Pilot

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

[Complete title: Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC]
Principal Investigator: Ramesh Rengan
Study Number: RTOG 1308
Phase: III

S1200: Acupuncture, Sham Acupuncture, or Wait List for Joint Symptoms Related to Aromatase Inhibitors in Pts W/Early-Stage Breast Cancer

[Complete title: Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer]
Principal Investigator: Julie Gralow, MD
Study Number: S1200
Phase: III

Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer

[Complete title: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer]
Principal Investigator: Christina Baik
Study Number: S1400
Phase: II/III

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
Principal Investigator: Scott Tykodi, MD
Study Number: SWOG 0931
Phase: III

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

[Complete title: A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin’s Lymphoma (NHL)]
Principal Investigator: Ajay Gopal, MD
Study Number: 20110654
Phase: I

Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer

[Complete title: A Phase III Clinical Trial of Intra-arterial TheraSphere in the Treatment of Patient with Unresectable Hepatocellular Carcinoma (HCC)]
Principal Investigator: William Harris
Study Number: 20111617
Phase: III

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

[Complete title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30-Positive Mature T-cell Lymphomas]
Principal Investigator: Andrei Shustov, MD
Study Number: 20121207
Phase: III

Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma

[Complete title: A Randomized, Open-Label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients with Advanced Classical Hodgkin Lymphoma]
Principal Investigator: Ajay Gopal, MD
Study Number: 20121311
Phase: III

A Phase 2 of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies

[Complete title: A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS 9973 in Subjects with Relapsed or Refractory Hematologic Malignancies]
Principal Investigator: Andrei Shustov, MD
Study Number: 20122094
Phase: II

A Study of ARN-509 in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN)

[Complete title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20130328
Phase: III

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

[Complete title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib]
Principal Investigator: William Harris
Study Number: 20130857
Phase: III

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

[Complete title: The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer]
Principal Investigator: Tia Higano, MD
Study Number: 20130917
Phase: II

A Safety Study of SGN-LIV1A in Breast Cancer Patients

[Complete title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer]
Principal Investigator: Jennifer Specht, MD
Study Number: 20131069
Phase: I

AZD8186 First Time In Patient Ascending Dose Study

[Complete title: A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated Advance Solid Malignancies, with Expansion to Assess the Pharmacodynamic Activity of AZD8186]
Principal Investigator: Tia Higano, MD
Study Number: 20131275
Phase: I

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer (D4190C00006)

[Complete title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Non-Small Cell Lung Cancer]
Principal Investigator: Sylvia Lee, MD
Study Number: 20131955
Phase: I/II

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

[Complete title: A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 20132066
Phase: II

MSB0010718C in Solid Tumors

[Complete title: A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications]
Principal Investigator: Nora Disis, MD
Study Number: 20132079
Phase: I

An Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol

[Complete title: An Open-Label, Extension (Rollover) Study Of Vemurafenib in Patients with BRAFV600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol.]
Principal Investigator: John Thompson, MD
Study Number: 20132215
Phase: III

Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

[Complete title: Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Waldenström’s Macroglobulinemia]
Principal Investigator: Edward Libby
Study Number: 20132221
Phase: I/II

Safety Study of Anti-LAG-3 in CLL, HL and NHL

[Complete title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas]
Principal Investigator: Ajay Gopal, MD
Study Number: 20132238
Phase: I

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (METRIC)

[Complete title: A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The “METRIC” Study)]
Principal Investigator: Jennifer Specht, MD
Study Number: 20132296
Phase: III

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

[Complete title: A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20132322
Phase: I

ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

[Complete title: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects with Metastatic Urothelial Cancer]
Principal Investigator: Evan Yu, MD
Study Number: 20140069
Phase: I

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)

[Complete title: A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of gefitinib in Combination with MEDI4736 (anti PD-L1) in Subjects with Non-Small Cell Lung Cancer(NSCLC)]
Principal Investigator: Laura Chow
Study Number: 20140532
Phase: I

A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of MEDI0680 (AMP-514) in Combination With MEDI4736 in Subjects With Advanced Malignancies

[Complete title: A Phase 1, Open-label Study to Evaluate the Safety and Tolerability of AMP-514 in Combination with MEDI4736 in Subjects with Advanced Malignancies]
Principal Investigator: Laura Chow
Study Number: 20140775
Phase: I

Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL

[Complete title: A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate) in Combination with Oral Leucovorin to Prevent or Reduce Mucositis in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20141037
Phase: II

Safety Study of SGN-CD70A in Cancer Patients

[Complete title: A Phase 1 trial of SGN-CD70A in patients with CD70-positive malignancies]
Principal Investigator: John Thompson, MD
Study Number: 20141105
Phase: I

A Phase I, Open-Label Study of MOXR0916 in Patients With Locally Advanced or Metastatic Solid Tumors

[Complete title: A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent To Patients with Locally Advanced Or Metastatic Solid Tumors]
Principal Investigator: Laura Chow
Study Number: 20141118
Phase: I

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (ERA 223)

[Complete title: A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)]
Principal Investigator: Tia Higano, MD
Study Number: 20141419
Phase: III

Phase 1b Acute Myelogenous Leukemia (AML) Study With ABT-199 + Decitabine or Azacitidine (Chemo Combo)

[Complete title: A Phase 1b Study of ABT-199 (GDC-0199) in Combination with Azacitidine or Decitabine in Treatment Naïve Subjects with Acute Myelogenous Leukemia Who Are = 65 Years of Age and Who Are Not Eligible for Standard Induction Therapy]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20141655
Phase: I/II

A Study of ARN-810 (GDC-0810) in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

[Complete title: An Open-Label, Phase I Study of ARN-810 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer]
Principal Investigator: Hannah Linden, MD
Study Number: 20141791
Phase: I

Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations

[Complete title: A Phase 1 Dose Escalation Study of ARQ 087 in Adult Subjects with Advanced Solid Tumors]
Principal Investigator: William Harris
Study Number: 20141857
Phase: I

A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer

[Complete title: A Phase 1 Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB, Stage IV, or Recurrent Non–Small Cell Lung Cancer]
Principal Investigator: Laura Chow
Study Number: 20141860
Phase: I

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916

[Complete title: A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA]
Principal Investigator: Edward Libby
Study Number: 20142069
Phase: I

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

[Complete title: Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects with Advanced Malignancies]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20142263
Phase: I

A Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

[Complete title: A Phase II, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients with HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received at Least One Prior Chemotherapy Regimen]
Principal Investigator: Christina Baik
Study Number: 20142268
Phase: II

Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Posivie Solid Tumors

[Complete title: Phase 1, Two-Part, Multiple Ascending Dose Study of Anti-HER2 Fcab FS102 in Breast, Gastric, and Other Solid Tumors]
Principal Investigator: Gabriela Chiorean
Study Number: 20142312
Phase: I

ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies

[Complete title: A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects with B-cell Malignancies]
Principal Investigator: Stephen Smith
Study Number: 20142444
Phase: I/II

Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)

[Complete title: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer]
Principal Investigator: Tina Rodriguez, MD
Study Number: 20150009
Phase: III

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)

[Complete title: A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Advanced/Unresectable or Metastatic Urothelial Cancer]
Principal Investigator: Evan Yu, MD
Study Number: 20150028
Phase: II

A Study Of PF-04518600 In Patients With Select Advanced Solid Tumors

[Complete title: A PHASE 1, OPEN-LABEL, DOSE ESCALATION STUDY OF PF-04518600 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC), MELANOMA, CLEAR CELL RENAL CELL CARCINOMA (RCC) OR SQUAMOUS CELL HEAD AND NECK CANCER (SCCHN)]
Principal Investigator: John Thompson, MD
Study Number: 20150061
Phase: I

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

[Complete title: A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20150094
Phase: I

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

[Complete title: An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects with Borderline Resectable Pancreatic Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150183
Phase: II

An Open-label, Phase 2 Study of ACP 196 in Subjects With Mantle Cell Lymphoma

[Complete title: An Open-label, Phase 2 Study of ACP-196 in Subjects with Mantle Cell Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20150224
Phase: II

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

[Complete title: A Phase 1b, Multi-center, Open-label, Dose Finding Study of CC-122 in Combination with Sorafenib in Subjects with Unresectable Hepatocellular Carcinoma]
Principal Investigator: William Harris
Study Number: 20150255
Phase: I

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

[Complete title: A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy]
Principal Investigator: Edward Libby
Study Number: 20150315
Phase: III

Safety Study of SEA-CD40 in Cancer Patients

[Complete title: A Phase 1, Open-Label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies]
Principal Investigator: Andrew Coveler, MD
Study Number: 20150420
Phase: I

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

[Complete title: A Phase II, multi-center, open-label, five-arm study to evaluate the efficacy and safety of oral ceritinib treatment for patients with ALK-positive non-small cell lung cancer (NSCLC) metastatic to the brain and/or to leptomeninges]
Principal Investigator: Christina Baik
Study Number: 20150427
Phase: II

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

[Complete title: A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma]
Principal Investigator: Edward Libby
Study Number: 20150434
Phase: II

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

[Complete title: A Phase I/II, open-label multi-center study to determine safety, pharmacokinetics and efficacy of GMI-1271 in combination with chemotherapy in patients with acute myeloid leukemia]
Principal Investigator: Pamela Becker, MD, PhD
Study Number: 20150436
Phase: I/II

Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer

[Complete title: A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel plus or minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel/Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer]
Principal Investigator: Gabriela Chiorean
Study Number: 20150466
Phase: I

A Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients With Locally Advanced or Metastatic Solid Tumors

[Complete title: A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors]
Principal Investigator: Laura Chow
Study Number: 20150515
Phase: I

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

[Complete title: A Phase 1b, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) with Vincristine and Dexamethasone in Adult Subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL)]
Principal Investigator: Ryan Cassaday
Study Number: 20150518
Phase: I

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

[Complete title: Phase 1/2 Open-Label Study of PF-06747775 (Epidermal Growth Factor Receptor T790M Inhibitor) in Patients with Advanced Epidermal Growth Factor Receptor Mutant (DEL 19 OR L858R +/- T790M) Non-Small Cell Lung Cancer]
Principal Investigator: Renato Martins, MD, MPH
Study Number: 20150645
Phase: I/II

The Vital Amyloidosis Study, a Phase 3, Multicenter Efficacy and Safety Study of NEOD001

[Complete title: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled. 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis]
Principal Investigator: Edward Libby
Study Number: 20150681
Phase: III

Study of Neukoplast (NK-92) Infusions in Patients With Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)

[Complete title: Phase II Study of NeukoplastTM (NK-92) Infusions in Patients with Unresectable Stage III (IIIB) or Distant Metastatic (IV) Merkel Cell Carcinoma (MCC)]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20150886
Phase: II

Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery

[Complete title: A Phase 1 exploratory study of the safety and ex vivo fluorescence of BLZ-100 administered by intravenous injection in adult subjects with solid tumors undergoing surgery.]
Principal Investigator: David Byrd, MD
Study Number: 20151060
Phase: I

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

[Complete title: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor]
Principal Investigator: Keith Eaton, MD, PhD
Study Number: 20151071
Phase: II

Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

[Complete title: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma]
Principal Investigator: Michi Shinohara
Study Number: 20151086
Phase: III

Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone

[Complete title: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.]
Principal Investigator: Robert Montgomery, MD
Study Number: 20151131
Phase: II

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

[Complete title: An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20151203
Phase: II

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium

[Complete title: An Open-Label, Multicenter, Phase 1 Study of Ramucirumab plus Pembrolizumab in Patients with Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, or Transitional Cell Carcinoma of the Urothelium]
Principal Investigator: Rafael Santana-Davila
Study Number: 20151222
Phase: I

PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) (ENLIVEN)

[Complete title: A Double-Blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath]
Principal Investigator: Elizabeth Loggers
Study Number: 20151460
Phase: III

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

[Complete title: A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies]
Principal Investigator: Laura Chow
Study Number: 20151522
Phase: I

Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)

[Complete title: A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma]
Principal Investigator: William Harris
Study Number: 20151610
Phase: III

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) With Peripheral T-Cell Lymphoma (PTCL)

[Complete title: A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) PLUS Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients with Peripheral T-Cell Lymphoma (PTCL)]
Principal Investigator: Andrei Shustov, MD
Study Number: 20151824
Phase: I

A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374) (CheckMate 374)

[Complete title: A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving Prior Anti-Angiogenic Therapy]
Principal Investigator: Scott Tykodi, MD
Study Number: 20152079
Phase: III

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

[Complete title: A Multi-center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma]
Principal Investigator: John Thompson, MD
Study Number: 20152183
Phase: II

A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)

[Complete title: Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-963558) In subjects with Virus-Positive and Virus-Negative Tumors]
Principal Investigator: Shailender Bhatia, MD
Study Number: 20152209
Phase: I/II

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

[Complete title: Phase I, Open-Label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination with INO-9012 in Men with Biochemically Relapsed (PSA) Prostate Cancer]
Principal Investigator: Heather Cheng
Study Number: 20152240
Phase: I

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2)

[Complete title: An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements]
Principal Investigator: Gabriela Chiorean
Study Number: 20152369
Phase: II

A Safety and Efficacy Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436)

[Complete title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and nivolumab clinical Trail Evaluation]
Principal Investigator: Andrei Shustov, MD
Study Number: 20152441
Phase: I/II

Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)

[Complete title: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY EVALUATING THE EFFICACY, SAFETY AND PHARMACOKINETICS OF ROVALPITUZUMAB TESIRINE (SC16LD6.5) FOR THIRD-LINE AND LATER TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY DELTA-LIKE PROTEIN 3-EXPRESSING SMALL CELL LUNG CANCER (TRINITY)]
Principal Investigator: Rafael Santana-Davila
Study Number: 20152704
Phase: II

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)

[Complete title: A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel in Subjects with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma who Progressed after First-Line Therapy with Platinum and Fluoropyrimidine]
Principal Investigator: Andrew Coveler, MD
Study Number: 20160019
Phase: III

A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma

[Complete title: A phase 1, open-label, dose-esclation study of SGN-CD19B in patients with relapsed or refractory aggressive B-Cell non-Hodgkin lymphoma]
Principal Investigator: Stephen Smith
Study Number: 20160030
Phase: I

A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer [IMpower 132]

[Complete title: A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN + PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN + PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER]
Principal Investigator: Rafael Santana-Davila
Study Number: 20160241
Phase: III

A Safety Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

[Complete title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma]
Principal Investigator: Edward Libby
Study Number: 2512.00
Phase: I

Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patient

[Complete title: A Phase I/II Study of Low Dose Cytarabine and Lintuzumab-Ac225 in Older Patients with Untreated Acute Myeloid Leukemia]
Principal Investigator: Johnnie Orozco, MD, PhD
Study Number: 2572.00
Phase: I/II

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

[Complete title: A Study Evaluating BPX-501 T cells and AP1903 for Prevention of GVHD after HLA-Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases]
Principal Investigator: Ann Woolfrey, MD
Study Number: 2615.00
Phase: I/II

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan in Patients With Non-Hodgkin's Lymphoma

[Complete title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980s) in combination with rituximab or polatuzumab vedotin (DCDS4501a) in combination with rituximab and a non-randomized phase Ib/II evaluation of polatuzumab vedotin in combination with obtinutuzumab in patients with relapsed or refractory B-cell non-Hodgkins's lymphoma]
Principal Investigator: Oliver Press, MD, PhD
Study Number: 2649.00
Phase: II

ety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

[Complete title: A Phase1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells after Partially Mismatched, Related, T Cell-Depleted HSCT]
Principal Investigator: Brenda Sandmaier, MD
Study Number: 2653.00
Phase: I

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT) (HELIOS)

[Complete title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)]
Principal Investigator: Michael Boeckh, MD
Study Number: 2707.00
Phase: III

Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

[Complete title: A Phase 1/2 Dose Escalation Safety and Pharmacokinetic Study of Multiple Intravenous Administrations of a Humanized Monoclonal antibody (SAR650984) Against CD38 in Patients with Selected CD38+ Hematological Malignancies]
Principal Investigator: Damian Green, MD
Study Number: 2724.00
Phase: I

Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer (EPOCH)

[Complete title: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy]
Principal Investigator: William Harris
Study Number: 7627
Phase: III

Trial of pIL-12 Electroporation Malignant Melanoma (IL12MEL)

[Complete title: A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Advanced Stage Cutaneous and in Transit Malignant Melanoma]
Principal Investigator: Shailender Bhatia, MD
Study Number: 7703
Phase: II

A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)

[Complete title: A Phase III Double-blinded, Placebo Controlled Study of XilonixTM for Improving Survival in Metastatic Colorectal Cancer]
Principal Investigator: Andrew Coveler, MD
Study Number: 8041
Phase: III

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML (RADIUS)

[Complete title: A Phase II, Randomized Trial of Standard of Care, with or without Midostaurin to Prevent Relapse following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia]
Principal Investigator: Bart Scott, MD
Study Number: 9037
Phase: II

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen (DAS181-2-05)

[Complete title: A Phase II, Randomized, Double-blind, Placebo-controlled study to examine the effects of DAS181 in immunocompromised subjects with Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen]
Principal Investigator: Michael Boeckh, MD
Study Number: 9108
Phase: II

A Safety and Pharmacology Study of MPDL3280A Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

[Complete title: A Phase Ib Study of the Safety and Pharmacology of MPDL3280A Administered with Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma F. Hoffmann-LaRoche/GO29383]
Principal Investigator: Brian Till, MD
Study Number: 9162
Phase: I

GS-5806 in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

[Complete title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract]
Principal Investigator: Michael Boeckh, MD
Study Number: 9208
Phase: II

GS-5806 in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract

[Complete title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract]
Principal Investigator: Alpana Waghmare
Study Number: 9212
Phase: II

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013)

[Complete title: A Phase Ib Multi-Cohort Trial of MK-3475 in Subjects with Hematologic Malignancies]
Principal Investigator: Damian Green, MD
Study Number: 9219
Phase: I/II

A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML

[Complete title: A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia (AML)]
Principal Investigator: Roland Walter, MD
Study Number: 9233
Phase: I

MK-8228 (Letermovir) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)

[Complete title: A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients]
Principal Investigator: Maggie Green
Study Number: 9235
Phase: III

A Study Evaluating ABT-199 in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)

[Complete title: A Phase 1/2 Study of ABT-199 in Combination with Low-Dose Cytarabine in Treatment-Naïve Subjects with Acute Myelogenous Leukemia Who Are >= 65 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy]
Principal Investigator: Roland Walter, MD
Study Number: 9237
Phase: I/II

Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors

[Complete title: A Phase 4 Safety and Efficacy Study of Bosutinib (Bosulif®) in Patients with Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated with One or More Tyrosine Kinase Inhibitors]
Principal Investigator: Vivian Oehler, MD
Study Number: 9238
Phase: IV

A Phase 1b Safety Study of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

[Complete title: A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1]
Principal Investigator: Seth Pollack
Study Number: 9290
Phase: I

Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant

[Complete title: Phase 1/2 Study of CaspaCide T Cells from an HLA-Partially Matched Family Donor after Negative Selection of TCR aß+ T Cells in Pediatric Patients Affected by Hematological Disorders]
Principal Investigator: Ann Woolfrey, MD
Study Number: 9311
Phase: I/II

A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

[Complete title: A Safety and Tolerability Trial of Crenolanib and Chemotherapy with Cytarabine and Anthracyclines in Patients with Newly Diagnosed Acute Myeloid Leukemia with FLT3 Activating Mutations]
Principal Investigator: Roland Walter, MD
Study Number: 9351
Phase: II

Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

[Complete title: A Phase 2, Open-Label, Single-Arm, Intra-Subject Dose-Escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects with Symptomatic Moderate or Severe Chronic GVHD inadequately responding to First or Second Line Therapy]
Principal Investigator: Stephanie Lee, MD, MPH
Study Number: 9367
Phase: II

Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection (CMX001 Adv)

[Complete title: A Phase 3, Open-label, Multicenter Study of the Safety/Tolerability and Efficacy of Brincidofovir (CMX001) for the Prevention of Adenovirus (AdV) Disease in Subjects with Asymptomatic AdV Infection at Risk of Progression and for the Treatment of Subjects with Localized or Disseminated AdV Disease]
Principal Investigator: Steven Pergam, MD
Study Number: 9371
Phase: III

A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

[Complete title: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.]
Principal Investigator: Roland Walter, MD
Study Number: 9382
Phase: I

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

[Complete title: A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects with Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor]
Principal Investigator: Bart Scott, MD
Study Number: 9435
Phase: II

SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission

[Complete title: A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients with Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR]
Principal Investigator: Roland Walter, MD
Study Number: 9498
Phase: I/II

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

[Complete title: A Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT-301 in Patients with Relapsed or Refractory CD25-positive Acute Myeloid Leukemia]
Principal Investigator: Roland Walter, MD
Study Number: 9513
Phase: I

Trial of CMB305 and Atezolizumab in Patients With Sarcoma (IMDZ-C232)

[Complete title: A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1]
Principal Investigator: Seth Pollack
Study Number: 9521
Phase: II

A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)

[Complete title: A Phase 2, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer]
Principal Investigator: Elizabeth Swisher, MD
Study Number: CO-338-017
Phase: II

A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects

[Complete title: SC-4003, Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects with Advanced BRAF V600-Mutation Positive Solid Tumors.]
Principal Investigator: Sarah Leary
Study Number: SC-4003
Phase: I/II

Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors

[Complete title: A Phase I-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients with Refractory Solid Tumors including Tumors of the Central Nervous System]
Principal Investigator: Sarah Leary
Study Number: SC-8002
Phase: I

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

[Complete title: A Phase I and expanded imaging study of BLZ-100 in pediatric patients with primary central nervous system tumors]
Principal Investigator: Sarah Leary
Study Number: SC-9009
Phase: I

Select a disease from the list below:

Limit results to studies enrolling:

OR

Search by Keyword, Investigator Name or Study ID#:

Limit results to studies enrolling:

OR

View all studies

Limit results to studies enrolling:

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials